Last updated: May 27, 2026
Kerendia is a branded finerenone (non-steroidal mineralocorticoid receptor antagonist) product marketed in the US by Bayer, with manufacturing and supply-chain execution split between Bayer’s internal network and third-party contract manufacturers. Public supplier visibility is highest for the US drug product and for finerenone API through DMF/OSD-linked organizations and the manufacturing sites that show up in FDA labeling and submissions.
What suppliers make finerenone (kerendia API)?
Finerenone supply is typically structured around (1) finerenone API manufacture under confidential DMFs and (2) drug-product assembly under cGMP contract manufacturing sites. For branded products like Kerendia, the most reliable supplier “proof points” are the drug master file references and the FDA-registered manufacturing sites named in regulatory filings tied to NDA/BLA supplements and labeling manufacturing sections.
API supply model for finerenone
- API manufacturer identification is driven by FDA DMF linkage to the approved NDA.
- API is then shipped under quality agreements to Bayer or to drug-product CMOs for formulation and finishing.
- Sterility is not required because finerenone is not an aseptic product. Quality controls focus on potency, polymorph control, residual solvents, and impurity profiles typical for small-molecule MRAs.
Drug-product (tablet) manufacturing and packaging suppliers
Kerendia is a solid oral dosage tablet. Drug-product supply typically includes:
- Tablet manufacturing (blending, granulation if used, compression, coating) at cGMP sites
- Finished-goods packaging (bottles/blisters), label printing, and serialization (where applicable)
For Kerendia specifically, FDA label “Manufactured for/Manufactured by” sections and manufacturing site listings in submissions function as the most actionable supplier sources for due diligence, licensing, and litigation risk mapping.
Which companies supply Kerendia to the US market?
Answer: Bayer is the marketed NDA holder for Kerendia in the US, and the finished product supply chain is executed through Bayer’s approved manufacturing network and licensed third-party manufacturing sites referenced in regulatory submissions and labeling.
US supply chain structure
- NDA holder/brand: Bayer
- Finished product manufacturing: FDA-registered cGMP sites named in labeling and submissions
- Packaging: typically performed at the same or at a separate registered site, again named in FDA submissions
How to confirm “active supplier” status in practice
For commercial and IP purposes, the “suppliers that matter” are the ones tied to (1) FDA-registered manufacturing facilities and (2) batch records that support commercialization runs.
Operationally, Kerendia supply diligence is performed via:
- FDA label manufacturing statements tied to the marketed product
- Inspection history for identified manufacturing sites
- DMF references for finerenone API-linked impurities and process controls
- Supply agreements between the NDA holder (Bayer) and CMO sites
What contract manufacturing organizations (CMOs) make Kerendia tablets?
Solid oral dose CMOs for small-molecule tablets are selected on scale, dissolution/coating capability, and impurity control. For a branded finerenone tablet, the CMO profile includes:
- Tablet compression and film-coating capability
- Strong analytical QC for MRAs including impurity profiling and stability programs
- Experience supporting controlled release profiles only if formulation requires it (Kerendia is not typically categorized as complex release)
Kerendia CMO identifications are normally confirmed by the manufacturing site statements on the US FDA label and the manufacturing sections of FDA approval letters and supplements. Those data points are the basis for supplier selection, risk scoring, and regulatory change control.
How do API and drug-product suppliers differ for finerenone?
Answer: API and finished tablet manufacturing are usually split. One or more finerenone API manufacturers provide bulk API to Bayer or a drug-product CMO. A separate set of cGMP sites performs formulation, tablet compression, coating, and packaging.
Key separation drivers
- API potency and impurity control require specific synthetic capabilities
- Tablet manufacturing requires formulation expertise, particle size/density control, and coating process control
- NDA change control depends on validated manufacturing processes and analytical methods
What is the Orange Book status of Kerendia and why it matters for suppliers?
Kerendia is a brand-name prescription drug. Supplier decisions for generics, authorized distributors, and potential licensees depend on exclusivity and patent landscape. If patent restrictions delay generic or authorized generic entry, demand is met by the incumbent supply chain until expiration or settlement.
Supplier/IP linkage
- Patent protections are enforced against “manufacture/use/sale” of infringing products
- Suppliers that support noninfringing manufacturing pathways must still meet regulatory and patent constraints
- CMO involvement does not eliminate infringement exposure if the product is made for sale
For exact Orange Book entries and patent-by-patent supplier implications, the key operational inputs are the listed patents and their expiration dates, which govern whether new suppliers or process changes can be adopted without triggering Hatch-Waxman risk.
What generic or biosimilar suppliers are likely to enter finerenone?
Finerenone is a small molecule, so “biosimilar” is not the pathway. The competitive threat is from:
- ANDA filers for the tablet dosage form
- Authorized generics via licensing
- Potential line-extension products if Bayer expands strengths or packaging formats
Entry risk for supply chain partners
- If a generic enters via Paragraph IV and succeeds, supply may shift quickly to ANDA-ready CMOs
- If entry is blocked by litigation or settlement, incumbent branded supply dominates
How strong is the finerenone patent estate as it affects sourcing?
Supplier diversification typically increases when:
- Patent exclusivity ends
- Patent litigation settles allowing noninfringing manufacturing
- Regulatory exclusivity or commercial restrictions are lifted
For Kerendia, sourcing decisions for new entrants usually hinge on:
- Method-of-use versus formulation coverage
- Composition-of-matter coverage for finerenone
- Device or packaging-specific claims only if any exist for the marketed presentations
Without a verified patent list and expiration schedule, supplier impact cannot be quantified for financing, licensing, or litigation strategy.
Key Takeaways
- Kerendia is supplied by Bayer as the marketed NDA holder, using FDA-approved cGMP manufacturing sites and associated packaging suppliers listed in regulatory materials.
- Finerenone API is typically made by separate API cGMP suppliers under DMF-linked regulatory support, then provided to tablet manufacturing CMOs or Bayer sites.
- Supplier diligence should be driven by FDA-registered manufacturing facility statements in labeling and submission records, not by secondary sourcing claims.
- Patent and exclusivity status governs when supplier diversification for generic manufacture becomes commercially feasible.
FAQs
- How can I identify the exact FDA-registered manufacturing site for Kerendia tablets?
- Who holds finerenone API DMFs used for Kerendia, and how is DMF identity verified in due diligence?
- What CMO capabilities are required to manufacture finerenone tablets to Bayer’s specifications?
- Do packaging suppliers for Kerendia differ from tablet manufacturing suppliers in FDA filings?
- How does Paragraph IV litigation change the supplier landscape for finerenone tablets?
References (APA)
No sources were included because the necessary verified supplier identifiers (specific company names, manufacturing site addresses, DMF holder names, and label manufacturing statements) were not provided in the prompt.
